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Arsenic exposure, through various routes, is associated with the development of 
cancer of the skin, lung, liver, kidney, and bladder.  Treatment of cells in culture with 
trivalent arsenicals has been shown to increase reactive oxygen species (ROS).  In 
particular, monomethylarsonous acid (MMAIII), a trivalent metabolite of arsenite, is 
highly cytotoxic and possibly carcinogenic.  Three trivalent arsenicals; arsenite, arsenic 
trioxide (ATO), and MMAIII, are also known inhibitors of the selenoprotein thioredoxin 
reductase (TrxR).  Selenium, an essential micronutrient in mammals, is needed in the 
form of selenocysteine for activity of this enzyme and other selenoproteins.  TrxR is part 
of a key component of the cell’s ability to defend against ROS.  It has been speculated 
that TrxR is also involved directly in selenium metabolism, but this has yet to be 
demonstrated in vivo.  The promoter region of the gene encoding the cytosolic TrxR 
(TrxR1) also contains an antioxidant responsive element (ARE).  The ARE is activated 
by the transcription factor, Nrf2, which is governed by the Nrf2/Keap1 response, and can 
be triggered by certain oxidants.  
ATO and arsenite both inhibited incorporation of selenium into selenoproteins.  
Auranofin, a gold chemotherapeutic inhibitor of TrxR1, also inhibited selenoprotein 
synthesis.  These results seem to support the hypothesis that TrxR1 is needed for 
selenoprotein synthesis.  However, siRNA mediated reduction of TrxR1 did not block 
incorporation of selenium into selenoproteins.  It is likely that ATO and auranofin are 
forming As-Se and Au-Se complexes, respectively.   
We also found that exposure of primary lung fibroblasts (WI-38) to MMAIII led to 
increased synthesis of TrxR1.  This increase was dependent on the activation of 
 iii
transcription of the TrxR1 gene, specifically mediated through the ARE element.  These 
results indicate exposure to MMAIII induces the Nrf2 response.   
The results obtained in these studies aid in both our understanding of the 
carcinogenic potential of arsenic as well as give new insight into the mechanism of action 
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CHAPTER ONE: LITERATURE REVIEW 
 
Selenium metabolism and selenoprotein synthesis 
 
Selenium is an essential trace element for mammals.  It was first discovered by 
the Swedish chemist Berzelius, and named after Selene, the goddess of the moon.  At first 
selenium was thought to be a toxin, but it is now recognized for it’s role in a family of 
proteins.  The form of selenium present in these proteins is selenocysteine, and this has 
been coined as the 21st amino acid.    
Selenoproteins are found in bacteria, archaea, and eukarya, but not in all species 
of each grouping.  Selenium metabolism slightly differs between the prokaryotic and 
eukaryotic worlds, however the focus here will be the eukaryotic, in particular mammals.  
There are 25 known selenoproteins in humans (Kryukov, Castellano et al. 2003).   The 
first protein to be identified to have selenocysteine at its catalytic site was glutathione 
peroxidase (Gpx) (Forstrom, Zakowski et al. 1978).  At least three targeted gene deletions 
of the selenoproteins, thioredoxin reductase 1 (TrxR1), TrxR2, and glutathione 
peroxidase 4  (GPx4), are embryonic lethal (Imai, Hirao et al. 2003; Nonn, Williams et al. 
2003; Jakupoglu, Przemeck et al. 2005). Also a deletion for the gene encoding for 
Selenocysteyl-tRNA[Ser]Sec(SectRNA[Ser]Sec), the SectRNA[Ser]Sec, results in early 
embryonic lethality (Bosl, Takaku et al. 1997).  These studies emphasize the importance 
of selenoproteins in development.   
Only a few groups of selenoproteins have been functionally characterized.  The 
function of most selenoproteins has yet to be elucidated.  Of the selenoproteins that have 
been classified they comprise of diverse functions, mainly anabolic metabolism and 
antioxidant defense.  The one thing that they have in common is at least one 
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selenocysteine (Sec) residue in every selenoprotein.  Selenoprotein synthesis is unlike 
traditional protein synthesis (Figure 1).  This is primarily a result Sec being encoded by 
what is usually a stop codon, UGA, which was first discovered in the protein GPx 
(Chambers, Frampton et al. 1986). 





Figure 1.   An overview of selenium metabolism in mammals  
Pictured above is an overview of selenium metabolism in mammals.  Selenide is utilized 
by SPS2 to produce selenophosphate.  This and the phosphoseryl-tRNA[Ser]Sec is used by 
soluble liver antigen (SLA) to generate the Sec-tRNA[Ser]Sec.  Figure adapted from (Papp, 




           Selenoprotein synthesis is a complex process involving a myriad of factors (Figure 
1).  The first of these is the unique tRNA.  Sec-tRNA[Ser]Sec is the only tRNA known to 
govern expression of an entire class of proteins.  Read-through of UGA codon requires a 
seryl-tRNA that is converted to SectRNA[Ser]Sec.  This tRNA only recognizes UGA 
codons coding for Sec, no other stop codons or serine codons.  The seryl-tRNA must be 
processed by several steps for the finished product of SectRNA[Ser]Sec. Phosphoseryl- 
tRNA[Ser]Sec kinase (PSTK) has been found to phosphorylate seryl- tRNA[Ser]Sec and is 
essential in the formation of SectRNA[Ser]Sec in eukaryotes (Carlson, Xu et al. 2004). The 
protein soluble liver antigen (SLA) was recently identified as the mammalian homolog of 
SelA.  This is the enzyme that dephosphorylates O-phosphoseryl -tRNA[Ser]Sec and 
accepts the selenium donor to make Sec-tRNA[Ser]Sec (Xu, Carlson et al. 2006). 
Another protein involved in selenium metabolism is selenophosphate synthetase 2 
(SPS).  Humans have two SPS proteins, where prokaryotes only have one.  SPS2 is also a 
selenoprotein (Guimaraes, Peterson et al. 1996).  This protein catalyzes the formation of 
selenophosphate from selenide, and is ATP dependent.  It has also been proposed that the 
selenophosphate produced by SPS2 is the selenium donor utilized by SLA to produce 
SectRNA[Ser]Sec (Xu, Carlson et al. 2006) .  
The next element that is required for selenoprotein synthesis is the selenocysteine 
insertion sequence (SECIS).  In eukaryotes the stem looped SECIS element is in the 3’ 
untranslated region, and may be kilobases away from the UGA codon which encodes for 
Sec (Berry, Banu et al. 1993).  This structure does share similar sequences among 
selenoproteins, but it does have a highly conserved secondary structure, the stem loop, 
that is necessary for Sec insertion (Krol 2002).  A single SECIS element is all that is 
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needed in selenoprotein synthesis, with the exception of Selenoprotein P (SelP), which 
contains 10 UGA codons coding for Sec (Castellano, Lobanov et al. 2005). 
 Efficient insertion of Sec also requires several other proteins, one of these being 
SECIS binding protein2 (SBP2).  To determine that SBP2 was essential to selenoprotein 
synthesis cell lysates were depleted of SBP2 and this resulted in an abolishment of 
selenoprotein synthesis.  When SBP2 was added selenoprotein synthesis was restored 
(Copeland, Fletcher et al. 2000).  SBP2 binds to the SECIS element (Lescure, Allmang et 
al. 2002)  and also interacts with the ribosome through the 28S rRNA, suggesting that 
SBP2 may pre-select ribosomes for Sec insertion (Copeland, Stepanik et al. 2001). 
Selenoprotein synthesis requires a specific elongation factor, EFSec.  This protein 
does not bind with the SECIS element directly.  It may bind to SECIS through interaction 
with SBP2, which it does bind to (Fagegaltier, Hubert et al. 2000).  Based on recent 
studies, EFSec helps with UGA translation efficiency.  It interacts with only 
SectRNA[Ser]Sec, and no other tRNAs.  EFSec recruits the Sec specific tRNA.  EFSec 
along with SBP2, and the SECIS element form a SectRNA[Ser]Sec complex for recruiting 
and delivering the SectRNA[Ser]Sec (Tujebajeva, Copeland et al. 2000)  
Recently two new factors have been discovered to be involved in selenoprotein 
synthesis.  Ribosomal protein L30 is one of these.  Similar to SBP2, L30 binds SECIS 
specifically, and may anchor SECIS complex onto the ribosome, this in turn stimulates 
UGA read-through activity (Chavatte, Brown et al. 2005).  Another factor is SECp43, 
which forms a complex with SectRNA[Ser]Sec.  When SECp43 is knocked down there is an 
overall decrease in selenoprotein synthesis (Xu, Mix et al. 2005), but the exact function 
has yet to be elucidated.  
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Thioredoxin reductase  
 Thioredoxin reductase (TrxR) is an antioxidant selenoprotein involved in 
maintaining the redox state of the cell.  TrxR had been discovered for many years before 
it was known that is contained selenocysteine (Tamura and Stadtman 1996).  Thiol-
disulfide reactions are important in controlling some proteins’ function and in protein 
tertiary structure.  Oxidation of SH groups could lead to improper folding or alter the 
biological activity.  The thioredoxin system is one of the major ways that the cell exerts 
thiol redox control.   
TrxR is a FAD containing homodimer, that is approximately 59 Kda in weight 
(Luthman and Holmgren 1982).  It is a member of the pyridine nucleotide-disulfide 
oxidoreducatse family of enzymes.  In mammals there are three isoforms; TrxR1 (the 
dominant form) is the cytosolic protein, TrxR2 is found in the mitochondria and may help 
protect the mitochondria from hydrogen peroxide (Lee, Kim et al. 1999), and TrxR3 is 
found only in the testis and will also has glutathione reductase activity (Sun, Kirnarsky et 
al. 2001).  All three of these isoforms are selenoproteins (Sun, Wu et al. 1999), with the 
UGA encoding Sec located at the penultimate C-terminal residue (Gladyshev, Jeang et al. 
1996).  Though there are three isoforms of TrxR in mammals, the focus of this thesis will 
be on the predominant cytosolic enzyme, TrxR1.       
TrxR acts as redox sensor (Sun, Wu et al. 1999).  Reactive oxygen species (ROS) 
have been shown to target the selenocysteine residue and oxidize the enzyme.  However, 
TrxR expression is increased with oxidative stress.  This could be a possible explanation 
for why the Sec residue is at the C-terminus (Sun, Wu et al. 1999).  In addition, the C-
terminus location of Sec allows for wider substrate recognition and easier access for 
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inhibitors.  Though thioredoxin (Trx) is the primary substrate of TrxR, it is also able to 
reduce lipoic acid, protein disulfide-isomerase, selenodiglutathione, lipid hydroperoxides, 
and dithiobis-nitrobenzoic acid (DTNB) (Holmgren 1977; Lundstrom and Holmgren 
1990; Bjornstedt, Kumar et al. 1992; Bjornstedt, Hamberg et al. 1995; Arner, Nordberg et 
al. 1996).  TrxR also catalyzes the reduction of selenite to selenide, which has led to 
speculation that TrxR is involved in selenoprotein synthesis (Bjornstedt, Odlander et al. 
1996).   
Regulation of TrxR1 expression 
The promoter of TrxR contains an antioxidant response element (ARE) (Rundlof, 
Carlsten et al. 2001).  This is the target DNA sequence recognized by the Nrf2/Keap1 
system.  Nrf2 is a transcription factor that is usually bound by Keap1.  When the cell 
undergoes oxidative stress Nrf2 is released from Keap1 (Itoh, Wakabayashi et al. 1999).  
This is triggered by a series of cysteine residues on Keap1 that sense changes in the redox 
environment (Lee and Johnson 2004).  It has been previously demonstrated that 
sulforaphane induces this response through TrxR (Hintze, Wald et al. 2003).   
The thioredoxin system 
The mammalian thioredoxin system consists of TrxR, thioredoxin (Trx), and 
NADPH (Rundlof, Carlsten et al. 2001).  Trx is a small 12 kDa redox active protein that 
is reduced by TrxR using NADPH (Figure 2).  Reduced thioredoxin is one of the major 
players for maintaining proteins in their reduced state. Two of the proteins that Trx serves 
as an electron donor are methionine sulfoxide reductases and peroxiredoxins (Chae, Kang 
et al. 1999; Kim and Gladyshev 2005), both of which act as antioxidants in the cell.  
Reduced Trx is also involved in an array of cellular processes including; synthesis of 
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deoxyribonucleotides (Laurent, Moore et al. 1964),  regulation of transcriptions factors 
such as Fos and Jun, nuclear factor-κB, AP-1, and p53 (Abate, Patel et al. 1990; Schenk, 
Klein et al. 1994; Ueno, Masutani et al. 1999), as an inhibitor of apoptosis signal-
regulating kinase (ASK1) (Saitoh, Nishitoh et al. 1998).  Extracellularly Trx has roles in 
immunoregulation as both a co-cytokine (Wakasugi, Tagaya et al. 1990) and as a 
chemokine, but does not act through a chemkine receptor (Bertini, Howard et al. 1999).  
Like TrxR1 and TrxR2, knockout studies with Trx resulted in embryonic lethality 
(Matsui, Oshima et al. 1996).   
Given the thioredoxin system’s involvement in a multitude of areas including cell 
proliferation and antioxidant defense, it is not surprising that TrxR is highly expressed in 
many types of cancers including breast, thyroid, prostate, liver, malignant melanoma, and 
colorectal (Berggren, Gallegos et al. 1996; Gladyshev, Factor et al. 1998).  Though the 
thioredoxin system is upregulated in many tumors, this stimulation it is not a requirement 
for all cancers.  Nonetheless, it does fit the requirements outlined in Hanahan and 
Weinberg’s hallmarks of cancer.  This consists of six altered traits that need to occur for 
cancer to develop.  This includes self-sufficiency in growth signals, insensitivity to 
antigrowth signals, evasion of apoptosis, sustained angiogenesis, and tissue invasion 
(Hanahan and Weinberg 2000).  Of these, only tissue invasion cannot be directly applied 
to the thioredoxin system.  Cell culture studies have been undertaken to examine the 
effect of knocking down TrxR.  In one study when TrxR1 was knocked down in mouse 
lung carcinoma cells (LLC1) the tumor phenotype reverted back to that of a normal cell 
as demonstrated through soft agar assays, morphology, and ability to produce tumors in 
mice (Yoo, Xu et al. 2006).  Another study used a similar construct in human 
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hepatocellular carcinoma cells knocking out TrxR, which inhibited growth of SMMC-
7721 cells (Gan, Yang et al. 2005).  Given these cell culture studies and that TrxR is 




Figure 2.   Overview of oxidoreductase activities of the thioredoxin system 
Presented is a schematic of the thioredoxin system as drawn from (Arner and Holmgren 
2000).  This is a depiction of the reduction of the oxidized Trx to the reduced form by 
TrxR with NADPH.  The reduced Trx is then used to reduce other proteins and serves as 
an electron donor.   
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Auranofin 
 Given that TrxR could be a target for cancer therapy, a specific inhibitor would be 
ideal.  One of these is the gold containing compound auranofin.  Auranofin has been used 
for the treatment of rheumatoid arthritis (Snyder, Mirabelli et al. 1987).  The proposed 
mechanism of this compound in the treatment of rheumatoid arthritis is through the 
inhibition of NF-κB.  This results in a decrease gene expression of proinflammatory 
cytokines (Yamada, Sano et al. 1999; Jeon, Jeong et al. 2000).  It is also an inhibitor or 
TrxR with a Ki of 4 nM in the presence of 50 µM thioredoxin.  At higher concentrations 
it can also inhibit glutathione reductase and glutathione peroxidase (Gromer, Arscott et 
al. 1998), however, these higher concentrations are not physiologically relevant.   
Though it is FDA approved for treatment of rheumatoid arthritis, there have been 
studies to promote its efficiency as cancer therapy.  In one such study cisplatin-resistant 
ovarian cancer cells were treated with up to 6 µM auranofin.  This raised levels of 
hydrogen peroxides in the cells and more importantly induced apoptosis.  Interestingly 
these cisplatin resistant cells had higher TrxR activities than the cisplatin sensitive cells, 
which were less effected by treatment with auranofin (Marzano, Gandin et al. 2007).  The 
upregulation of TrxR, could be key in development of auranofin as a chemotherapeutic.        
Arsenic 
 Arsenic exists in many forms, inorganic and organic, trivalent and pentavalent.  
Arsenic exposure is primarily through the water supply, in particular artesian well water 
(Tseng 1977). Contamination of arsenic in the water supply is a significant human health 
issue in parts of Taiwan (Tseng 1977), Chile (Borgono, Vicent et al. 1977), Argentina 
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(Hopenhayn-Rich, Biggs et al. 1998), Bangladesh (Nickson, McArthur et al. 1998), and 
regions of China (Xia and Liu 2004).   
Inorganic arsenite (trivalent) or arsenate (pentavalent) are the most likely forms to 
be taken up by the body, since these are the most prevalent in the water supply.  After 
entering the body arsenate is reduced to arsenite (Tapio and Grosche 2006).  Next, the 
inorganic arsenite or arsenate undergoes a methylation pathway, in the liver, and is 
excreted in the urine (Figure 3).  Methylated forms of arsenic are excreted more easily 
than inorganic.  
Traditionally the methylation pathway has been thought of the as detoxification of 
arsenic.  Recently, this has been questioned for several reasons.  Monomethylated forms 
have been found to be the most cytotoxic, with pentavalent species not as cytotoxic as 
trivalent species.  Trivalent monomethylated species may help to contribute the effects of 
arsenite exposure (Styblo, Del Razo et al. 2000).  Monomehtlyarsonous acid (MMAIII) 
has been found to be more cytotoxic than arsenite in liver cells (Petrick, Ayala-Fierro et 
al. 2000).  Interestingly humans excrete much more MMAIII than other species of 
mammals (Vahter 2002).  Rodents primarily excrete dimethylarsinous acid (DMA).   
It should be noted that rodents are less prone to arsenic induced cancer 




Figure 3.   Metabolism and methylation of arsenic 
Pictured above is the methylation pathway for arsenic.   Arsenic enters the bloodstream 
as the pentavalent arsenate or as the trivalent arsenite through environmental exposure.  It 
then undergoes a series of reduction and methylation reactions and is excreted in the 
urine.  Drawn from (Cohen, Arnold et al. 2006).   
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  Chronic arsenic exposure is associated with: skin cancer, hyperpigmentation 
(presence of dark pigmentation), hyperkeratosis (benign wart-like growths on the skin) 
and Blackfoot disease (Tseng 1977).   In addition to skin cancer, exposure to arsenic has 
been implicated in cancer of the lung, kidney, liver, and bladder (Hopenhayn-Rich, Biggs 
et al. 1998). According to a recently published 50 year study conducted in Chile, there is 
an approximate 10 year latency period between exposure and mortality from arsenic 
induced cancer from high levels of exposure in the water supply (Marshall, Ferreccio et 
al. 2007).  Arsenic exposure has also been associated with diabetes mellitus, 
hypertension, and cardiovascular and cerebrovascular diseases (Chen, Hsueh et al. 1995; 
Chiou, Huang et al. 1997; Tseng, Tseng et al. 2002; Tseng, Chong et al. 2003).  
Arsenicosis is most often the result of exposure from arsenic contaminated drinking 
water.  Arsenicosis includes symptoms of skin lesions that include hyperpigmentation, 
hypopigmentation, keratosis, hyper keratosis, skin ulceration, and skin cancers (Yu, Sun 
et al. 2007).   
 Even though arsenic exposure is associated with an array of diseases and cancers, 
it has yet to be proven to cause cancer directly. Arsenite does not directly cause 
mutagenesis, but in conjunction with other compounds can produce mutations.  In one 
study the use of the alkylating agent n-methyl-n-nitrosourea co-induced mutations in 
Chinese hamster ovary cells when treated simultaneously with arsenite (Li and Rossman 
1989).  Another study with the same cell line observed an increase in mutations when 
treated with ultraviolet light (Yang, Chen et al. 1992).  Arsenite results in a pro-
angiogenesis effect as determined by the chick chorioallantoic membrane model (Mousa, 
O'Connor et al. 2007).  Angiogenesis is important aspect of tumor formation as these are 
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the blood vessels that feed them. In another study, MMAIII has been shown after 52 
weeks of low exposure to induce hyperproliferation, anchorage independent growth, and 
tumorigenicity in an immortalized human urothelial cell line (Bredfeldt, Jagadish et al. 
2006).  This study of MMAIII is the most recent to suggest that MMAIII be classified as a 
carcinogen.  
One popular hypothesis states that oxidative stress and free radicals, produced 
during arsenic exposure, are linked to cancer (Kligerman and Tennant 2007). Reactive 
oxygen species (ROS) include; hydrogen peroxide, superoxide anion, singlet oxygen, and 
hydroxyl radical.  Each of these species can cause damage to DNA and protein, but the 
hydroxyl radical is the most often associated with DNA damage.  Usually a free 
transition metal such as iron is needed for the hydroxyl radical to cause DNA damage in 
the presence of peroxide (Kitchin and Ahmad 2003). ROS can cause DNA damage by 
causing single strand breaks, deletions, and hydroxylation of 2’-deoxyguanosine.  In 
addition, oxidation at the C8 position of guanine may cause mispairing with adenine 
during DNA replication resulting in a mutation (Kitchin 2001). 
From a recent epidemiological study in Taiwan, arsenic exposure resulted in 
increased reactive oxidants and decreased antioxidant capacity in vivo (Wu, Chiou et al. 
2001). Arsenite and MMAIII have been shown to cause lipid peroxidation, protein 
carbonylation, and oxidative DNA damage in urothelial carcinoma cell lines (Wang, Jan 
et al. 2007).  Similarly, in an in vivo study, higher levels of serum lipid peroxides were 
found in populations exposed to arsenic through well water.  This also correlated with 
lower levels of nonprotein sulfhydryls (Pi, Yamauchi et al. 2002). Treatment with 
arsenite induced free radical formation, most likely hydroxyl radicals produced by 
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superoxide, as determined by fluorescence and ESR (Liu, Athar et al. 2001).  In another 
study arsenite at high concentrations produced superoxide and hydroxyl radicals and 
induced DNA damage to cells in culture (Shi, Hudson et al. 2004).  While arsenite 
produces ROS more quickly, MMAIII can also induce formation of ROS (Eblin, Bowen et 
al. 2006).    Also, of all the arsenic species MMAIII results in higher levels of ROS 
(Schwerdtle, Walter et al. 2003).   
In addition to oxidative stress, arsenic can cause a variety of changes that are 
associated with development of cancer.  Arsenite causes chromosome aberrations and 
sister chromatid exchange (Barrett, Lamb et al. 1989).  Arsenic, in particular arsenite, 
suppresses DNA repair capacity.  One mechanism could be the decreased expression of 
the nucleotide excision repair gene ERCC1 both in vitro and in vivo (Andrew, Burgess et 
al. 2006). Arsenic has also been associated with changes in methylation patterns. One 
study found exposure to low levels of arsenite (nanomolar range) for 2-4 weeks caused 
hypo and hypermethlyation of DNA in transformed kidney and lung cells (Zhong and 
Mass 2001).  Another study found hypermethlyation of cytosines in the p53 promoter 
with A549 cells treated with low levels of arsenite for an extended period of time (Mass 
and Wang 1997).  A study of a constant low dose long exposure of arsenite in rat liver 
cells resulted in gene expression changes in cell cycle regulation, signal transduction 
pathways, stress response, apoptosis, cytokine production, and growth factor production 
(Chen, Liu et al. 2001).   
Arsenic trioxide 
 Arsenic trioxide (ATO) is a trivalent species of arsenic.  Even though in high 
doses it is toxic and is associated with carcinogenesis, it is also a FDA approved 
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treatment of acute promyelocytic leukemia (APL) that is known as Trisenox.  It has been 
approved for the use of APL since 1998 (Bradley 2000). Trials are underway in testing 
the effectiveness of ATO against solid tumors such as; gastric, ovarian and cervical, 
bladder, neuroblastoma, glioblastoma (a type of brain tumor), breast, and lung 
(bronchogenic carcinoma) (Dilda and Hogg 2007).  
 ATO is thought to work by several mechanisms.  At low concentrations (0.1-0.5 
µM), ATO induces differentiation of malignant promyelocytes through inactivation of the 
promyelocytic leukemia-retinoic acid receptor α (PML-RARα) (Zhang, Westervelt et al. 
2000).  This protein is involved in the malignancy of APL by blocking differentiation.  At 
higher concentrations (0.5-2.0 µM), ATO induces apoptosis, which could be a result of 
several mechanisms.  The fist is that ATO causes a vast amount of ROS from which the 
cell cannot recover (Jing, Dai et al. 1999).  Another study has also shown that ATO 
induces apoptosis through triggering the release of cytochrome c and activation of 
caspase-3 in APL cells (Cai, Shen et al. 2000).  However, a recent study has shown that it 
also inhibits the selenoprotein TrxR, and this could be part of the mechanism (Lu, Chew 
et al. 2007).   
Arsenic and selenium interactions 
 Arsenic and selenium are known to interact in what is known as the mutual 
sparing effect, first described by Moxon during studies of seleniforous grains (Moxon 
1938).  This implies that when selenium levels are low, arsenic levels are higher, and 
when arsenic levels are low, selenium levels are higher.  This mutual sparing effect has 
also been demonstrated in animal and cell culture studies in which levels of selenium and 
arsenic were varied (Levander 1977; Styblo and Thomas 2001).   
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 Another key finding in the interaction of selenium and arsenic was the discovery 
of the seleno-bis(S-glutathionyl) arsinium ion (Gailer, George et al. 2002; Gailer, George 
et al. 2002).  This was excreted in the bile of rabbits treated with selenium and arsenic.  
Recently we published a study on the affect of trivalent arsenicals on selenoprotein 
synthesis in a keratinocyte model.  It was found that arsenite decreased selenium 
incorporation into selenoproteins. However, MMAIII induced selenium incorporation into 
TrxR, while decreasing selenium incorporation into smaller selenoproteins, such as 
cGPx.    
 In the studies reported in this thesis, our goal was to answer two key questions; 1) 
Is TrxR1 required for selenoprotein synthesis?  and 2) What is the molecular mechanism 
of the induction of TrxR1 by exposure to MMAIII? 
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CHAPTER TWO: MATERIALS AND METHODS 
Materials 
 Sodium selenite and sodium arsenite were obtained from Acros Organics (Geel, 
Belgium).  75Se radioisotope (in the form of selenite), was purchased from University of 
Missouri Research Reactor (MURR, Columbia, MO).  35S-methionine/cysteine label was 
obtained from Amersham BioSciences (Piscataway, NJ).  Auranofin was from Axxora 
LLC (San Diego, CA).   ATO was obtained from Acros Organics (Geel, Belgium).   
MMAIII was from Dr. William Cullen, Department of Chemistry, University of British 
Columbia (Vancouver, Canada).  All other reagents used were of the highest grade 
obtainable.   
Cell culture 
  A549 cells were obtained from the American Type Culture Collection 
(Manassas, VA).  Cells were cultured in Dulbecco’s modification of Eagle’s medium 
(DMEM) with L-glutamine, sodium pyruvate, and 4.5 g/L glucose.  This was 
supplemented with 100 µg/mL streptomycin, 100 IU/mL penicillin (Mediatech, Herndon, 
VA), and 10% fetal bovine serum (FBS) (Equi-tech Bio, Kerrville, TX).   WI-38 cells 
were from the American Type Culture Collection and were cultivated in Eagle’s 
Minimum Essential Medium (EMEM) supplemented with Earle’s balanced salt solution, 
non-essential amino acids, and sodium pyruvate. Supplementation of the EMEM medium 
included 10% FBS and 50 µg/mL streptomycin, and 50 IU/mL penicillin.  All cells were 
maintained at 37°C, with 5% CO2, with a humidified atmosphere as a monolayer.  
Population doublings of WI-38 cells were recorded at each passage by cell counting 
using a hemacytometer, and no cells were used in experiments that exceeded a population 
doubling of 34.0.   
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Cell viability assay 
To determine the cytotoxicity of arsenite, MMAIII, ATO, and auranofin, MTT 
assays were performed.  Cells were cultured in 96 well plates, at approximate 
concentrations of 2,500-10,000 cells per well (depending on the compound being tested) 
in 100 µL of appropriate media for the cell type.  Cells were grown to approximately 
70% confluence before treatment, with the exception of ATO treated cells which were 
grown to 40% confluence.  Arsenite was tested at concentrations of 1, 3, 9, 18, 36, 72, 
144 µM.  MMAIII was tested in the following concentrations in A549: 1, 3, 6, 9, 13, 17, 
21 µM, and 0.2, 0.5, 1, 3, 6, 9, 12, 15, 18, 21, 24, 28 µM in WI-38.  Auranofin was 
assessed at 0.1, 0.25, 0.5, 0.75, 0.9, 1, 3, 7, 10, 20, 30, 50 µM.  ATO was tested at 0.25, 
0.5, 0.7, 0.9, 1, 3, 7, 10, 20, 40, 50, 70 µM in A549 cells. Cells were incubated for 24 
hours with either arsenite, MMAIII, auranofin before adding 1.2 mM of a tetrazolium dye, 
3- (4,5 dimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium bromide (MTT) (Amresco, Solon, 
OH).  For cytotoxicity of ATO the cells were incubated for 48 hours before addition of 
MTT.  Plates were then incubated for 4 hours at 37°C in a humidified atmosphere of 5% 
CO2.  To solubilize the dye, 100 µL of a stop solution (10% SDS and 5 mM HCl) was 
added and the plates were incubated an additional 14-20 hours before analysis.  The 
reduced formation of product was measured at an absorbance of 570 nm using a 
Molecular Devices, SpectraMax 190 spectrophotometer (Sunnyvale, CA).  Cell viability 
was calculated as a percentage compared to control with error being the standard 
deviation from triplicate wells.   
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Radioisotope labeling 
A549 or WI-38 cells were cultured in 6-well plates and grown to 70% confluence.  
Approximately 2 µCi of 75Se, in the form of selenite (University of Missouri), and 10 nM 
of unlabeled sodium selenite were added to each well.  Just prior to labeling, various 
concentrations of arsenite (0, 2, 6, or 10 µM in A549 cells), MMAIII (0, 2, or 6 µM in 
A549, and 0, 0.2, or 2 µM in WI-38 cells), or ATO (0, 1, 2.5, 5, or 10 µM in A549 cells) 
were added.  However, when adding auranofin (0.1, 0.25, 1 or 3 µM) cells were treated 
for 4 hours, to allow inhibition of TrxR, prior to addition of isotope.  The cells were 
incubated at 37°C with 5% CO2 for 24 hours before harvesting when treated with 
arsenite, MMAIII, or auranofin.  Cells treated with ATO were harvested after 48 hours of 
treatment.  To monitor how arsenite, auranofin, and ATO effect overall protein synthesis 
30 µCi of 35S, in a cysteine/methionine mixture, was added to each well, with A549 cells 
cultured in a cysteine/methionine free DMEM.           
Cells were harvested by washing the well with Dulbecco’s phosphate-buffered 
saline (DPBS), then upon removal adding 1x trypsin-EDTA and incubating at 37°C for 4 
minutes.  Cells were collected by centrifugation and washed with DPBS.  Cell pellets 
were resuspended in 200 µL of lysis buffer (50 mM tricine (pH 8.0), 0.1 mM 
benzamidine, 0.5 mM EDTA, and 1 mM DTT).  Cells were lysed by sonication for 6-8 
sec, at a power setting of 4 W, using a Model 100 sonic dismembrator (Thermo Fisher 
Scientfic, Pittsburgh, PA).  The lysates were then centrifuged at 13,000 rpm for 7 minutes 
at 4°C.  Lysates were analyzed for 75Se using a Wallac Wizard Gamma Counter, Model 
1470 (PerkinElmer, Wellesly, MA).  35S isotope levels in cell extracts were determined 
by liquid scintillation using a Packard TriCarb 2900 TR counter (PerkinElmer, Waltham, 
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MS).  Protein concentration was quantified through Bradford assay according to the 
method in (Bradford 1976) using bovine serum albumin as a standard.  Approximately 
15- 25 µg of protein (depending on the study) from crude cell extract was separated by 
SDS-PAGE gel (5% stacking gel and 15% resolving gel), and exposed to a 
phosphoimaging screen (Molecular Dynamics).  Selenoproteins were visualized and in 
some cases quantified, using Image Quant software (Molecular Dynamics, Sunnyvale, 
CA).     
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of TrxR1 
gene expression 
Cells were cultured in 25 cm2 flasks and treated with 0, 2, or 10 µM arsenite, or 
MMAIII for 24 hours.  Cells were harvested by washing with 1x DPBS, and then 
incubated for 4 min with 1x trypsin-EDTA.  The cells were then washed with 1x DPBS 
treated with diethylpyrocarbonate (DEPC) (0.1%).  RNA was isolated with a 
ChargeSwitch Total RNA Cell Kit (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions.  Concentrations of RNA were determined by ultraviolet 
(UV)-visible spectrophotometry at 260 nm using an Agilent 8453 UV-visible 
spectrophotometer (Ageliant Technologies, Santa Clara, CA).  Complimentary DNA 
(cDNA) was synthesized from 0.5 µg of RNA using an iScript cDNA synthesis kit 
(BioRad, Hercules, CA) according to the manufacturer’s instructions.   
 Primers used included (listed forward then reverse) TrxR1: 5’AGCTCAGT 
CCACCAATAGTGA-3’ and 5’-GGTATTT TTCCAGTCTTTTCAT-3’; β-actin: 5’-
CATGTACGTTGCTATCCA-3’ and 5’-CTCCTTAATGTCACGCACGAT-3’; Trx: 5’-
GCAGATCGAGAGCAAGACTG-3’ and 5’-CTCCAGAAAATTCACCCACC-3’; 
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cGPx: 5’-GGACTACACCCAGATGAA-3’ and 5’-CAAGGTGTTCCTCCCTCGTAG-
3’.  All RT-PCR was done with a Bio-Rad I-Cycler (BioRad, Hercules, CA).  Each 
reaction was a total volume of 25 µL consisting of SYBRgreen supermix (Bio-Rad, 
Hercules, CA) four oligonucleotides at a concentration of 0.2 mM, forward and reverse 
primers (at a concentration of 0.2 µM each), and 5 µL of 1:100 diluted cDNA.  Reaction 
conditions were as follows; the first cycle at 95.0°C for 3 minutes, followed by 40 cycles 
95.0°C for 10 sec and 55.0°C for 45 sec.  With the cGPx-specific primers the following 
reaction conditions were used; a single cycle at 94.0°C for 3 minutes, subsequent 40 
cyles of 94.0°C for 30 sec, 55°C for 30 sec, and 70.0°C for 30 sec.  Melt curves were 
used to determine formation of single product.  Efficiency of amplification of each primer 
pair was calculated with a 10-fold dilution series with untreated cDNA.  The Pfaffl 
method (Pfaffl 2001) was used to determine the relative expression (fold) for each of the 
genes of interest using β-actin as an internal standard.  
 TrxR activity assays 
A549 or WI-38 cells were cultured in 75 cm2 flasks in appropriate cell culture 
media.  Cells were treated with varying concentrations of arsenite (0, 2, or 6 µM), 
auranofin (0, 0.25, 1, or 3 µM), or MMAIII (0, 2 or 6 µM in A549 cells and 0, 0.2, or 2 
µM in WI-38 cells) for 24-48 hours (depending upon the compound being tested) before 
harvesting as described above.  Cells pellets were resuspended in a lysis buffer of 5 mM 
potassium phosphate pH 7.4 and 0.5 mM EDTA and sonicated as described above.   
Crude cell extracts were centrifuged at 11 krpm for 7 min at 4 °C.  NADPH dependent 
reduction of dithiobis-nitrobenzoic acid (DTNB) was determined according to Levander, 
with minor modifications (Smith and Levander 2002).  Protein concentration was 
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determined by Bradford assay as described above and according to (Bradford 1976). 
Cells extracts were diluted in a buffer consisting of 10 mM potassium phosphate pH 7.4, 
154 mM potassium chloride, and 1 mg/mL of bovine serum albumin (BSA) to a final 
concentration of 1 mg/mL.  The reaction buffer consisted of 500 mM potassium 
phosphate pH 7.8, 50 mM potassium chloride, 10 mM EDTA, and 0.2 mg/mL BSA.  To 
each well containing reaction buffer in a 96-well plate, 24 mM NADPH (dissolved in 
0.01% sodium bicarbonate) was added before 20 µM DTNB. To measure the gold 
inhibitable activity to differentiate TrxR from glutathione reductase (GR), cell extracts 
were pre-incubated with 1 µM auranofin for 20 minutes at room temperature to allow for 
complete inhibition of TrxR.  50 µg of protein was used to begin the reactions in a 96 
well plate, and each individual sample was run in duplicate. Reduction of DTNB was 
followed using a SpectraMax 190 spectrophotometer (Molecular Devices, Sunnyvale, 
CA) at 412 nm, at a temperature of 37°C, taking readings every 15 sec for 3 minutes.  
Slopes were determined for each sample, and the rates of samples incubated with 
auranofin were subtracted to determine total TrxR activity.  Activity of TrxR is given as 
nmol/min/mg of protein, with standard deviation as the error.    
Transient siRNA knockdowns 
 A549 cells were seeded in 6 well plates and grown to 60% confluence.  siRNA 
targeting the mRNA encoding mitogen activated protein kinase1 (MK), Trx, and TrxR1 
were obtained through Qiagen (Valencia, CA).  A non-silencing fluorescent control was 
used to determine siRNA transfection efficiency.  Transfection complexes were prepared 
by a mixture of serum free media, HiPerfect Transfection Reagent (Qiagen, Valencia, 
CA), and 5 nM target siRNA, and incubated for 10 minutes at room temperature to allow 
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transfection complexes to form.  This was added dropwise to cells.  Immediately 
following addition of 5 nM siRNA, cells were treated with 3 µM auranofin to inhibit 
existing TrxR.  Cells were incubated for 24 hours with siRNA and auranofin before 
removing media and labeling with 2 µCi of 75Se (selenite) and incubating an additional 
24 hours.  Cells were harvested as described above in previous labeling experiments.  Trx 
and TrxR1 knockdowns were assessed at the mRNA level by real-time reverse 
transcriptase-PCR as described above.   
Promoter fusion luciferase constructs assay 
Luciferase promoter fusion constructs of human wild-type TrxR1, mutant TrxR1, 
and rat quinone reductase (QR) were a generous gift from Dr. Korry Hintze (Department 
of Nutrition and Food Sciences, Utah State University).   Cells were seeded in 24-well 
tissue culture plates.  A549 cells were seeded at a concentration of 100,000 per well, and 
WI-38 cells at 60,000 per well in 500 µL of the appropriate medium.  Transfection 
complexes were prepared with 1 µg of plasmid DNA (pDNA) of all three constructs in 
A549, 1 µg of pDNA of TrxR1 and mutated TrxR1 constructs in WI-38, and 2 µg of QR 
in WI-38 cells.  In addition to the pDNA the following was added to complete the 
transfection complexes; Superfect reagent (Qiagen, Valencia, CA) was added in a 7.5 
µL/1 µg pDNA ratio, 540 µL Optipro serum free medium (Gibco, Carlsbad, CA), and 2.5 
ng of a control plasmid expressing Renilla luciferase (PRL-SV40) (Promega, Madison, 
WI) for all transfections, with the exception of 12.5 ng of PRL-SV40 for QR 
transfections in WI-38 cells.  Cells were incubated with transfection complexes and 300 
µL of the appropriate medium with serum for 3 hours.  The medium was then changed 
and MMAIII added in the following concentrations in triplicate; 0, 2, or 6 µM in A549 
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cells and 0, 0.2, or 2 µM in WI-38 cells, and incubated for 24 hours before assaying.  
Luciferase assay was completed with the Dual Luciferase Reporter Assay System 
(Promega, Madison, WI) according to the manufacturer’s instructions with the exception 
of using 2x passive lysis buffer, followed by scraping for the WI-38 cells.  A Glomax 
luminometer (Promega, Madison, WI) was used to measure luminescence.  Data was 
plotted as a fold ratio of luciferase to renilla activity, with standard deviation as error.     
Statistical Analysis 
 All statistical analyses were performed with Microsoft Excel for Mac 2004 
(Microsoft, Redmond, WA).  Unpaired t-tests or one way ANOVA were performed when 
appropriate.  All significance was evaluated at p<0.05.   
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CHAPTER THREE: RESULTS AND DISCUSSION - INHIBITORS OF 




 TrxR is a selenoprotein involved in controlling the redox state of the cell.  Its 
primary substrate, thioredoxin (Trx), is required for many cellular activities including: 
cell proliferation, DNA synthesis, and regeneration of peroxyredoxins and methionine 
sulfoxide reductase (Laurent, Moore et al. 1964; Chae, Kang et al. 1999).  In in vitro 
TrxR can also reduce selenite to selenide (Bjornstedt, Odlander et al. 1996).  This has led 
to speculation that TrxR is somehow involved in selenoprotein synthesis, since selenide 
is the form of selenium utilized by selenophosphate synthetase2 (SPS2).    
In this study, three inhibitors of TrxR were used to observe their effects on 
selenium metabolism.  The first compound tested was arsenite (Figure 4 A), a trivalent 
inorganic form of arsenic mainly found in arsenic contaminated water supplies.  Arsenic 
exposure is associated with cancer of the liver, lung, kidney, and bladder (Kitchin 2001).  
ATO is also a trivalent form of arsenic that is used to treat acute promyelocytic leukemia 
(Figure 4 B).  It was recently found to be an inhibitor of TrxR (Lu, Chew et al. 2007).  
Auranofin is a well-known inhibitor of TrxR (Gromer, Arscott et al. 1998) (Figure 4 C).  
It is also a current therapy for rheumatoid arthritis.   
We tested the hypothesis that TrxR is involved in selenium metabolism.  This was 
accomplished by looking at the effects of three known inhibitors of TrxR on selenium 
metabolism and siRNA knockdowns targeting TrxR1 and Trx.         
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Figure 4.  Structures of arsenite, ATO, and auranofin 
Pictured above are the structures of arsenite (A), ATO (B), and auranofin (C) as obtained 





Evaluation of cytotoxicity of arsenite in A549 cells 
MTT assays were used to determine toxicity of arsenite in A549 cells.  Cells were 
treated for 24 hours with varying concentrations of arsenite.  Results from these 
experiments show that at approximately 100 µM of arsenite, there is a 50% reduction in 
cell viability (Figure 5).  This is a non-physiologically relevant concentration since it is 
thought that environmental exposure to arsenic is mimicked in cell culture by levels in 
the low micro molar or nanomolar levels (Hughes 2002).  A549 cells are somewhat 
resistant to arsenite as compared to human keratinocytes used in another related study 
(Ganyc, Talbot et al. 2007).  HaCat cell viability was reduced to 50% by approximately 
22 µM arsenite.  Since the overarching goal is to determine the impact of arsenite on 
selenoprotein synthesis, from the results of this assay it was determined that future 
concentrations used to treat A549 cells would be in the 1-10 µM range, and that these 
concentrations would not significantly affect cell viability during short term (24-48 










Figure 5.  A549 cells are resistant to exposure to low micromolar levels of arsenite 
Cytotoxicity of arsenite was determined in A549 cells after 24 hours of exposure using 
MTT assays.  The absorbance of the treated cells was compared to untreated cells to 
determine the relative percent cell viability.  Data points are the mean of triplicate wells, 
with the error plotted as standard deviation.  The data plotted are from a representative 
experiment taken from three separate independent experiments.   
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Arsenite treatment of cells reduces selenium incorporation into selenoproteins 
 In order to determine whether exposure to arsenite affects selenium metabolism, 
we followed selenium incorporation into selenoproteins by radioisotope labeling with 
75Se.  The results indicate that exposure to A549 cells to 6 µM of arsenite, a decrease in 
general selenoprotein synthesis occurs, particularly TrxR (Figure 6).  At 10 µM there is a 
near abolishment of selenium incorporation into selenoproteins.  It must be noted that the 
cells are still viable at this point, with only minor rounding.  Arsenite does not inhibit 
general protein synthesis as determined by 35S-methionine/cysteine labeling in add in 
new data as it is generated. 
 TrxR is the predominant selenoprotein expressed in A549 cells, and it is well 
established that this cell line expresses very little cGPx (Avissar, Finkelstein et al. 1996).  
In a previous study, using a keratinocyte cell line, cGPx served as one of the markers for 
selenoprotein synthesis (Ganyc, Talbot et al. 2007).  This cannot be accomplished with 
A549 cells.  However, selenium incorporation into smaller (unidentified) selenoproteins 
decreases along with TrxR in the presence of arsenite.  
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Figure 6.  Exposure of A549 cells to arsenite inhibits incorporation of selenium into 
selenoproteins 
A549 cells were exposed to arsenite (0, 2, 6, or 10 µM) immediately followed by 
radiolabeling with 75Se (selenite) for 24 hours.  Cells were subsequently harvested and 30 
µg of protein were separated by SDS-PAGE (15%).  Selenoproteins were visualized by 
phosphorimage analysis.  TrxR was identified as the predominant labeled selenoprotein 
by its size (59 KDa) using a standard protein marker (not shown).  
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Arsenite does not significantly effect the level of mRNA encoding TrxR1 
To determine whether arsenite affects production of TrxR1 mRNA, real time RT-
PCR was used.  Arsenite had no significant effect on the mRNA levels that encode TrxR1 
(p>0.05) (Figure 7).  Even in cells treated with 10 µM arsenite, there is no significant 
change in the levels of transcript.  This differs from the labeling results in which arsenite 
decreased TrxR synthesis in a concentration dependent manner beginning at treatment 
with 6 µM.  TrxR1 was chosen as the selenoprotein marker given its abundance in A549 
cells (Avissar, Finkelstein et al. 1996).  This demonstrates that arsenite is not effecting 
TrxR1 at the level of transcription, and must be effecting incorporation of selenium into 
selenoproteins.   It should be noted that this is in contrast to data that was previously 
obtained in a skin cell model in which TrxR1 expression levels increased with the 
addition of arsenite (Ganyc, Talbot et al. 2007).  At the biochemical level arsenite is 
known to be a potent inhibitor of TrxR1 (Holmgren 1977).   Based on these results two 
possible mechanisms can explain the decreased incorporation of selenium.  The first, that 
direct inhibition of TrxR by arsenite reduces the level of selenide in the cell, assuming 
TrxR is needed for this step (Bjornstedt, Odlander et al. 1996).  The second that a 
glutathione conjugate, GSSeAs-, is formed, blocking selenium metabolism.   
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Figure 7.  Treatment of A549 cells with arsenite does not significantly alter the levels 
of mRNA encoding TrxR1 
Cells were treated for 24 hours with 0, 2, or 10 µM arsenite followed by isolation of RNA 
for real time RT-PCR analysis.  β-actin was used as an internal standard.  Relative 
expression (fold) plotted is an average of multiple experiments with cultures grown in 
triplicate in each experiment.  Error bars represent standard deviation.  No statistical 
significance was found between TrxR1 transcript levels in cells treated with arsenite as 





Arsenite inhibits TrxR activity 
Previous studies have shown that arsenite inhibits TrxR in vitro (Holmgren 1977). 
To determine whether that arsenite treatment of A549 cells results in altered TrxR 
activity, cells were cultured with arsenite for 48 hours at 0, 2, and 6 µM.  At 2 µM 
arsenite TrxR activity is reduced by about 50% (Table 1).  There was complete inhibition 
of TrxR in cells treated with 6 µM arsenite.  Since arsenite is not effecting TrxR at the 
level of transcription, nor protein levels as determined by immunoblotting (data not 
shown), it may be acting solely as an inhibitor of TrxR. Whether this inhibition is tied to 
overall selenoprotein synthesis is still unknown.  Nonetheless, this supports the notion 
that TrxR is involved in selenoprotein synthesis.  It is known that it can reduce selenite to 
selenide in vitro and it has been speculated that it does have a role in selenoprotein 
synthesis, but this has yet to be demonstrated (Bjornstedt, Odlander et al. 1996).  It then 
becomes important to examine other inhibitors of TrxR to see if they produce the same 
decrease in selenoprotein synthesis.        
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Table 1.  Effect of exposure to arsenite on TrxR activity 
TrxR activities were determined by DTNB assay as previously described (Smith and 
Levander 2002).  A549 cells were cultured in the presence of 0, 2, or 6 µM arsenite for 
48 hours prior to harvesting.  The average activity is derived from a multiple experiments 








0 µM 7.71 1.53 
2 µM 3.89 1.28 





Cytotoxicity of arsenic trioxide 
 Since arsenite inhibited TrxR activity in A549 cells, another trivalent arsenical, 
ATO, was examined.  ATO is used for treatment of acute promyelocytic leukemia, and 
differs from arsenite structurally (Figure 4).  Often in cell culture studies examining the 
effects of ATO, arsenite is used interchangeably, even though it is not the trivalent 
arsenical that is used in cancer therapy.  ATO was also recently identified as an inhibitor 
of TrxR (Lu, Chew et al. 2007). It then becomes important to confirm that ATO causes 
the same phenotypic changes as arsenite regarding selenoprotein synthesis. 
 As with arsenite, an MTT assay was used to determine the toxicity of ATO in 
A549 cells.  At 60 µM ATO there is a 50% reduction in cell viability (Figure 8).  In a 
recent study it was found that 0.25 µM inhibited TrxR in vitro, and cell growth decreased 
with exposure to 2.5 µM ATO in human breast cancer (MCF-7) cells (Lu, Chew et al. 
2007). Based on these results we carried out studies to follow selenium metabolism using 





Figure 8.  Toxicity of ATO in A549 cells 
Cytotoxicity of ATO was determined by MTT assay.  A549 cells were treated with a 
range of concentrations of ATO for 48 hours before addition of MTT. The absorbance of 
reduced tetrazolium dye after solublization was compared to untreated cells to determine 
the relative viability of cells.  Data points are the mean of triplicate wells, with the error 
plotted as standard deviation.  This is a representative experiment taken from three 
independent experiments.   
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ATO blocks incorporation of selenium into selenoproteins 
 Even though they are used interchangeably in cell culture studies, it is important 
to determine whether ATO exhibits the same phenotype as arsenite on selenium 
metabolism when cultured with A549 cells.  Similar to arsenite, ATO treatment of A549 
cells leads to decreases in selenoprotein synthesis as demonstrated by 75Se radiolabeling 
(Figure 9 A).  This inhibition is observed in cells treated with a concentration of 2.5 µM 
and continues in a concentration dependent manner.  In addition, ATO does not effect 
general protein synthesis as determined by 35S labeling studies (Figure 9 B).  In a 
previous study, 2.5 and 5 µM ATO were found to inhibit TrxR1 in MCF-7 breast cancer 
cells by 40% (Lu, Chew et al. 2007). It is interesting that two trivalent inorganic 
arsenicals have the same effect on selenoprotein synthesis where one, arsenite, is 
associated with cancer, and the other, ATO, is associated with the treatment of cancer.  
The next step was to look at another known inhibitor of TrxR, one that did not contain 





Figure 9.  ATO inhibits selenoprotein synthesis, but not general protein synthesis in 
A549 cells 
A549 cells were cultured in DMEM and treated with either 0, 1, 2.5, or 5 µM ATO and 
labeled with 2 µCi of 75Se (A) or 35S (B) in triplicate for 48 hours.  Cells were harvested 
and 15 µg of protein from extracts were separated by SDS-PAGE (15%).  Selenoproteins 
(75Se) and general protein synthesis (35S) were visualized by phosphorimage analysis.    
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Cytotoxicity of auranofin 
 Auranofin is a known inhibitor of TrxR (Gromer, Arscott et al. 1998).  It is a gold 
compound that is currently used in the treatment of rheumatoid arthritis.  As with arsenite 
and ATO, the cytotoxicity of auranofin in A549 cells was determined by MTT assay.  
Cells were treated with auranofin for 24 hours at varying concentrations.  A 50% 
reduction in cell viability is observed in cell treated with 15 µM auranofin (Figure 10).  
A549 cells are much more sensitive to auranofin than ATO and arsenite.  This assay was 
used to determine which concentrations of auranofin should be used in radiolabeling 
studies that would be sub-toxic to A549 cells.  From the MTT assay and the literature on 
auranofin inhibiting TrxR, it was decided that 0, 0.1, 0.25, 1 and 3 µM auranofin would 
be used in studies to follow selenium metabolism.    
 




Figure 10.  Auranofin is toxic to A549 cells 
Cytotoxicity of auranofin was determined by MTT assay.  A549 cells were treated with a 
range of concentrations of auranofin, in triplicate for 24 hours before the MTT dye was 
added.  This is a representative experiment taken from three independent experiments.  
Each point is an average of three wells, and error is standard deviation.     
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Auranofin inhibits selenoprotein metabolism 
Based on its ability to inhibit TrxR, we determined whether treatment of A549 
cells with auranofin would affect incorporation of selenium into selenoproteins.  
Auranofin indeed inhibited incorporation of selenium into selenoproteins in a 
concentration dependent manner (Figure 11 A).  At treatment with 1 µM there is a 
significant decrease in selenoprotein synthesis.  Nearly all incorporation of selenium into 
selenoproteins is abolished, with the exception of TrxR, in cells treated at 1 or 3 µM 
auranofin.  There is a concentration dependent decrease in levels of TrxR seen beginning 
at 1 µM.  Neither treatment with 0.1 or 0.25 µM auranofin had any effect on 
selenoprotein synthesis.  Auranofin does not inhibit general protein synthesis as shown 
by 35S labeling (Figure 11 B).  This was tested at the same concentrations used to 
examine the effect of auranofin on selenoprotein synthesis.     
The data presented thus far supports the hypothesis that TrxR is critical to 
selenoprotein synthesis.  So far, three inhibitors of TrxR have decreased incorporation of 
selenium into selenoproteins.  Though it must be made certain that TrxR is inhibited in 




Figure 11.  Auranofin treatment of A549 cells results in inhibition of incorporation 
of selenium into selenoproteins, but does not inhibit general protein synthesis 
A549 cells were cultured in DMEM and treated with either 0, 0.1, 0.25, 1, or 3 µM 
auranofin and radiolabeled with either 75Se (A) or 35S (B) 4 hours after addition of 
auranofin.  Protein from cell extracts were separated by SDS-PAGE (15%) and visualized 
by phosphorimaging.  
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Auranofin treatment of A549 cells leads to lower TrxR activity 
Cells were cultured with increasing concentrations of auranofin and subsequently 
harvested after 24 hours.  TrxR activity was determined by following the reduction of 
DTNB (Smith and Levander 2002).  At treatment with 1 µM auranofin a significant 
decrease in TrxR activity is observed (Table 2).  With treatment at 3 µM the activity is 
decreased even further, to approximately one-fifth of that of control.  These results were 
expected since auranofin is a known potent inhibitor of TrxR both in vitro and in vivo 
(Gromer, Arscott et al. 1998).  
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Table 2.  Treatment of A549 cells leads to inhibition of TrxR 
A549 cells were treated with increasing concentrations (0, 0.25, 1, or 3 µM) of auranofin 
for 24 hours.  TrxR activities were determined by DTNB assay, as previously described.  








0 µM 10.4 1.86 
0.25 µM 10.3 1.83 
1 µM 7.82 1.19 





Neither Trx or TrxR are required for selenoprotein synthesis 
To confirm that TrxR1 is involved in the metabolism of selenium, transient 
siRNA knockdowns were used.  It is not only important to look at the effect of a 
knockdown of TrxR1, but also its primary physiological substrate Trx.  The possibility 
exists that the lack of reduced Trx could be responsible for the decrease in selenoprotein 
synthesis observed when cells were treated with known TrxR inhibitors.  It is also 
important to inhibit the existing TrxR in the cells with chemical inhibitors to reduce 
existing enzyme activity.  This was accomplished by simultaneously treating A549 cells 
with 3 µM auranofin, a concentration that inhibits TrxR activity (Table 2), and siRNA 
targeting Trx, TrxR1, or a negative control for 24 hours.  Cells were treated with siRNA 
and auranofin for 24 hours then the media was removed and replaced with fresh media 
without auranofin.  75Se was added to monitor selenoprotein synthesis.  This pre-
treatment with auranofin was tried in various iterations, with similar to results to the ones 
presented (Figure 12), before deciding which method was the best for inhibiting the 
existing TrxR and successfully knocking down TrxR1 and Trx.  It was also important to 
have a transient knockdown of a protein unrelated to selenoprotein synthesis to ensure 
that any effects seen with the knockdowns of TrxR1 or Trx would be specific.  For this 
we chose Map kinase1 (MK), which has no known linkage to selenium metabolism, 
selenoprotein synthesis, Trx, or TrxR1.   
Efficiency of transfection was determined by using a non-specific fluorescent 
probe.  Transfected cells were counted by direct optical fluorescence microscopy.  The 
transfection efficiency was found to be 65.7%.     
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From the labeling with 75Se, it was shown that a knockdown of TrxR1 did not 
result in a decrease in overall selenoprotein synthesis (Figure 12).  The same was true for 
the knockdown of its substrate, Trx.  The only band that shows a significant decrease in 
any selenoprotein was that of TrxR, when the siRNA was introduced into the cells.  
There is no change in the incorporation of selenium into selenoproteins in cells without 
siRNA treatment demonstrating that the exposure to auranofin and its removal did not 
reduce new selenium incorporation.  Cells treated with MK siRNA also did not exhibit 
any changes in selenoprotein synthesis.  We then sought to confirm that both expression 
of TrxR1 and Trx were decreased before further speculation can be made about the role 
of TrxR1 in selenoprotein synthesis.      
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Figure 12.  siRNA knockdowns of Trx and TrxR1 reveal no role in selenoprotein 
synthesis 
A549 cells were treated with 5 nM siRNA targeting the mRNA molecules encoding map 
kinase1 (MK), thioredoxin (Trx), or thioredoxin reductase 1 (TrxR1).  Cells were pre-
treated with 3 µM auranofin to inhibit existing TrxR.  After 24 hours the media was 
removed, replaced with fresh media without auranofin and 75Se was added.  The cells 
were then incubated an additional 24 hours to assess selenium incorporation.  20 µg of 
protein from cell lysates were separated by SDS-PAGE (15%).  Radiolabeled 
selenoproteins were visualized by phosphorimaging.    
 
                                 
                                                                               
 49
Expression levels of TrxR1 and Trx in siRNA treated cells 
 
 To confirm that siRNA knockdowns were efficient, the mRNA levels of both 
TrxR1 and Trx were analyzed.  Cells treated with the Trx siRNA construct show a 
significant decrease in Trx mRNA expression levels as determined by real time RT-PCR 
(Figure 13 A).  TrxR1 mRNA levels are unaffected by the Trx siRNA construct.  
Similarly, TrxR1 mRNA levels are severely decreased in cells treated with TrxR1 siRNA 
(Figure 13 B).  Trx mRNA levels are unchanged by treatment with TrxR1 mRNA.  This 








Figure 13.  Confirmation of siRNA knockdowns using real time RT-PCR analysis of 
Trx and TrxR1 mRNA levels 
Real-time RT-PCR was used to monitor efficiency of the Trx and TrxR1 knockdowns by 
analyzing mRNA levels.  β-actin was used an internal standard for analysis.  Trx (A) 
mRNA levels were indeed much lower in cells treated with Trx siRNA as compared to 
control and TrxR1 knockdowns.  Likewise, TrxR1 (B) mRNA levels were reduced by 
treatment with TrxR1 siRNA.  Mean relative expression (fold) in (A and B) is derived 
from a representative experiment with duplicate cultures that were analyzed in triplicate.  
Error bars represent standard deviation.   
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CHAPTER FOUR: CONCLUSIONS - INHIBITORS OF THIOREDOXIN 
REDUCTASE AND THEIR EFFECT ON SELENIUM METABOLISM 
 
There has been much speculation on the role of TrxR in selenoprotein synthesis 
(Kumar, Bjornstedt et al. 1992; Ganther 1999; Papp, Lu et al. 2007).  It is known that 
TrxR can reduce selenite to selenide (Bjornstedt, Odlander et al. 1996).  Selenide is the 
primary form of selenium utilized by selenophosphate synthetase 2 (SPS2) to produce 
selenophosphate (Tamura, Yamamoto et al. 2004).  Though this reaction with TrxR 
occurs in vitro, there is lacking in vivo data.   
 In this study we have demonstrated that TrxR is not likely involved in 
selenoprotein synthesis.  Even though three known inhibitors of TrxR decreased selenium 
incorporation into selenoproteins, knockdown of TrxR1 expression resulted in no change 
in incorporation of selenium into selenoproteins.  The existing TrxR was also inhibited by 
auranofin to ensure that if TrxR had a role there would be a decrease in selenoproteins as 
demonstrated by the 75Se radiolabeling.  It was also shown that treatment of A549 cells 
with 3 µM auranofin would inhibit the existing TrxR in A549 cells (Table 2).  The 
targeted siRNA experiments strongly suggest that TrxR is probably not involved in 
selenoprotein synthesis.  It then becomes important to discuss the possible mechanism of 
the phenotypes seen with the three inhibitors of TrxR.    
 The three inhibitors of TrxR all exhibited the same phenotype of decreasing 
selenium incorporation into selenoproteins.  Instead of TrxR having a part in 
selenoprotein synthesis, these compounds are likely acting as an inhibitor of selenium 
metabolism as well as inhibiting TrxR.  There has been evidence for arsenite to bind 
glutathione and selenium, creating a glutathiolated selenium arsenic compound (Gailer, 
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George et al. 2002).  This metabolic inhibition could be also occurring with ATO and 
auranofin.  If these inhibitors of TrxR are binding free selenide in the cell, this could 
reduce the amount of selenide available to selenophosphate synthetase 2 (SPS2), which in 
turn would reduce the amount of selenium for selenoprotein synthesis.  
In the case of ATO, the inhibition of selenium metabolism also gives insight to 
the possible mechanism of this drug.  It has been traditionally thought that ATO worked 
by inducing differentiation of malignant promyelocytes through inactivation of the 
promyelocytic leukemia-retinoic acid receptor α (PML-RARα) (Zhang, Westervelt et al. 
2000).  However, recently it was found that ATO was an inhibitor of TrxR (Lu, Chew et 
al. 2007).  From the data in this study, inhibiting the cell’s ability to produce new 
selenoproteins could also be contributing to the chemotherapeutic effects of ATO.   
Auranofin likely binds to the selenocysteine in TrxR, which is near the end of the 
C-terminus of the protein.  It is possible that auranofin binds selenols in general, and that 
the location of the selenocysteine in TrxR is more easily bound to than other 
selenoproteins. In addition, TrxR is also one of the most abundant selenoproteins.  
Auranofin as an inhibitor of selenium metabolism may also shed light onto the 
mechanism on which it works as a treatment for rheumatoid arthritis.  The mechanism for 
action of auranofin is still not understood.  This data provides evidence that a decrease in 
selenium metabolism could be partially responsible for the effectiveness of this drug.  
There have also been cell culture studies looking at the potential of auranofin as a 
cancer therapy.  In one such study, it was found that auranofin induced apoptosis in 
ciplatin resistant ovarian cancer cells, and caused the release of cytochrome c (Marzano, 
Gandin et al. 2007).  Auranofin also induced apoptosis in acute promyelocytic leukemia 
 53
cells, the type of cancer that ATO is used to treat, when combined with retinoic acid 
(Kim, Jin et al. 2004).  Given this and the data presented here that auranofin reduces 
selenium incorporation into selenoproteins at a sub-toxic level, there is a chance that it 
could be useful in cancer therapy, particularly in cancers that require high levels of 
selenium due to increased expression of TrxR.  
All three of the compounds tested in this study are inhibitors of TrxR.  It is known 
that deficiency of TrxR1 by stable transfections of siRNA constructs causes a reversal of 
a tumorgenic phenotype to normal in mouse lung carcinoma cells and in mice (Yoo, Xu 
et al. 2006).  It is not yet known that a decrease in selenoprotein synthesis would exert the 
same effect.  It has been demonstrated here that these inhibitors of TrxR, also inhibit 
selenium metabolism, but likely not through inhibition of TrxR.  From the siRNA studies, 
it was shown that TrxR is not involved in selenoprotein synthesis.  The decrease of 
selenium incorporation into selenoproteins is likely due to a decrease in available in the 
form of selenide.  This decrease in selenoprotein synthesis could be key in understanding 
how these compounds work against cancer cells.  Further studies to assess the chemical 
reactivity of selenide with ATO and auranofin should be carried out to confirm this 
hypothesis.           
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CHAPTER FIVE: RESULTS AND DISCUSSION - MONOMEHTYLARSONOUS 




 Arsenic exposure is a worldwide public health concern.  Mammals metabolize 
arsenic in the liver by a series of methylation reactions.  One of these metabolites is 
MMAIII.  MMAIII has been shown to be the most cytotoxic of the trivalent arsenicals in 
cell culture (Petrick, Ayala-Fierro et al. 2000).  It has also been shown to cause lipid 
peroxidation, protein carbonylation, and oxidative DNA damage in cell culture studies 
(Wang, Jan et al. 2007).  MMAIII exposure has induced hyperproliferation, anchorage-
independent growth, and tumorigenicity in an immortalized human urothelial cell line 
(Bredfeldt, Jagadish et al. 2006).  This recent study has suggested that MMAIII be 
classified as a carcinogen.  The mechanism remains undetermined on how these 
carcinogenic phenotypes arise with exposure to MMAIII. 
 The selenoprotein TrxR is regulated by an antioxidant response element in its 
promoter sequence (Rundlof, Carlsten et al. 2001).  This is under the control of the 
Nrf2/Keap1 system.  The transcription factor Nrf2 is usually bound to the protein Keap1 
(Itoh, Wakabayashi et al. 1999).  Keap1 contains redox reactive cysteines and is able to 
sense changes in the cellular redox environment.  When the cell undergoes oxidative 
stress Nrf2 is released from Keap1 and translocates to the nucleus, and activates ARE 
containing genes.  These genes are part of the cell’s defense against oxidants.  Different 
compounds can induce the Nrf2/Keap1 response.  It was found that sulforaphane induced 
TrxR through this system (Hintze, Wald et al. 2003).        
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 TrxR is also expressed in higher levels in many tumors including breast, thyroid, 
prostate, liver, malignant melanoma, and colorectal (Berggren, Gallegos et al. 1996; 
Gladyshev, Factor et al. 1998).  Reduced thioredoxin, TrxR’s primary substrate, is 
involved in DNA synthesis, and integral to cell proliferation (Laurent, Moore et al. 1964).  
Recently it has been suggested that TrxR not only be a marker for cancer, but a potential 
target for cancer therapy (Arner and Holmgren 2006).   
 
A comparison of the cytotoxicity of MMAIII between A549 and WI-38 cells 
 As with the previous studies, cytotoxicity, in this case the cytoxicity of MMAIII, 
was first determined in A549 and WI-38 cells.  A549 cells are an alveolar type II 
epithelial-like adenocarcinoma line.  Contrastingly, WI-38 cells are a primary lung 
fibroblast, which act accordingly to the Hayflick model and have been used extensively 
for studies on cellular senescence (Hayflick and Moorhead 1961; Place, Noonan et al. 
2005).  Our goal is to determine the effects of MMAIII on selenoproteins in a transformed 
and primary cell line.   
 A549 cells were found to be more resistant to MMAIII than WI-38 cells (Figure 14 
A and B).  At approximately 12 µM treatment in A549 cells there is a 50% reduction in 
cell viability (Figure 14 A).  In WI-38 cells treated with 6 µM MMAIII there is a 50% 
decrease in cell viability (Figure 14 B).  Thus, MMAIII is much more cytotoxic in the 
primary cells.  This could be due to a variety of reasons.  One could be that uptake of 
MMAIII is not as efficient in A549 cells.  Another could be that during the transformation 






Figure 14.  MMAIII is more cytotoxic in WI-38 cells, than in A549 cells 
A549 (A) and WI-38 (B) cells were cultured in the appropriate medium (different for 
each cell type) and treated with MMAIII for 24 hours before adding MTT dye.  After 
solubolize the dye, the plates were analyzed after 24 hours at 570 nm. 
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Selenium incorporation into TrxR increases in WI-38 cells with addition of MMAIII 
 To determine the effects of MMAIII on selenium metabolism, both cell types were 
exposed to MMAIII and labeled with 75Se (selenite) radioisotope.  Treatment with MMAIII 
resulted in no change in selenium incorporation into selenoproteins in A549 cells as 
determined by radiolabeling with 75Se (Figure 15 A).  Even at 6 µM, the highest 
concentration tested, there is no change in selenoprotein synthesis.  The levels of MMAIII 
tested in both cell types were sub-toxic.  In a previous related study, it was found that 
MMAIII did not effect general protein synthesis as determined by 35S 
(cysteine/methionine) radiolabeling (Ganyc, Talbot et al. 2007). 
However, exposure to MMAIII in WI-38 cells caused an increase in what is 
believed to be TrxR (the band labeled I) synthesis (Figure 15 B).  To our knowledge, no 
prior 75Se labeling studies have been conducted in this cell line, and so the selenoproteins 
have not been identified by where they would appear and with what intensities by 
phosphorimage analysis.  This increase was seen at treatment with 1 and 2 µM MMAIII. 
While TrxR was increasing, selenium incorporation into smaller selenoproteins, possibly 
cellular glutathione peroxidase (cGPx), was decreasing (Figure 15 B).  Further analysis of 
the densitometry of the band possibly representing TrxR (I) revealed a two-fold increase 
at these concentrations compared to control (Figure 15 C).  The densitometry analysis of 
the smaller selenoprotein band II showed a sharp decease with increasing exposure to 
MMAIII.  This contrast in an increase in TrxR and decrease in smaller selenoproteins 






Figure 15.  TrxR increases synthesis with exposure to MMAIII, at the expense of 
smaller selenoproteins 
A549 cells (A) were treated with 0,2, or 6 µM MMAIII, and WI-38 cells (B) with 0, 0.2, 
or 2 µM MMAIII in triplicate.  Immediately following exposure to MMAIII cells were 
labeled with 75Se (selenite) and incubated for 24 hours before harvesting.  25 µg of 
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protein was separated by SDS-PAGE (15%).  Selenoproteins were visualized by 
phosphorimage analysis.  TrxR was identified by using a standard protein marker (not 
shown) in A549 cells.  Band intensity of WI-38 gel (C) was determined by densitometry 
analysis with ImageQuant software.   
 60
MMAIII increases TrxR1 mRNA levels in WI-38 cells 
 After examining the effect of MMAIII on selenium incorporation into 
selenoproteins, the next step was to begin to identify the mechanism behind the observed 
phenotypes.  This included looking at mRNA expression, activity, and regulation of 
TrxR.  Expression levels of the gene encoding TrxR1were monitored by real time RT-
PCR.  In A549 cells cultured with 0, 2, or 6 µM MMAIII there was no significant change 
in TrxR1 mRNA levels (Figure 16 A).  This correlates with the radiolabeling by 75Se, in 
which treatment with MMAIII did not effect TrxR levels.   
 In contrast to the A549 cells, treatment with 2 µM MMAIII did cause a significant 
increase in mRNA expression levels of TrxR1 (*, p<0.05) (Figure 16 B).  However, 
treatment with 0.2 µM did not elicit the same effect.  This also shows a relationship to the 
radiolabeling data in which 2 µM MMAIII increased what is believed to be TrxR 
synthesis by two-fold.   
 Treatment of WI-38 cells with MMAIII also caused mRNA levels of cGPx to 
decrease (Figure 16 C).  At exposure to 2 µM MMAIII there was a significant decrease.  
This also correlates with the labeling data in this cell line.  There was a decrease with 
exposure to MMAIII in selenium incorporation into smaller selenoproteins, including a 
band we believed to be cGPx (Figure 15 B).  The RT-PCR data suggests that this band is 
more than likely cGPx.  cGPx levels are not assessable in A549 cells due to the extremely 










Figure 16.  Treatment with MMAIII in WI-38 cells leads to a significant increase in 
mRNA levels encoding TrxR1 
A549 (A) and WI-38 (B and C) cells were cultured with  0, 2, or 6 µM (A549) or 0, 0.2, 
or 2 µM (WI-38) MMAIII for 24 hours.  Cells were harvested and RNA isolated for real-
time RT-PCR analysis.  β-actin was used as an internal standard.  Relative expression 
(fold) plotted is a representative experiment with cultures grown in triplicate for A549 
cells and duplicate for WI-38 cells.  (A) and (B) are graphs representing expression of 
mRNA levels of TrxR1, and (C) is expression of mRNA levels of cGPx.  Each culture 
was analyzed in triplicate.  Error bars represent standard deviation.  Statistical 
significance was determined by Student’s t-test.  
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MMAIII inhibits activity of TrxR in A549 cells and varies activity in WI-38 cells 
 MMAIII is a known potent inhibitor of TrxR in vitro (Lin, Cullen et al. 1999).  
Both cell lines were cultured with increasing concentrations of MMAIII for 48 hours 
before harvesting and determining TrxR activity by DTNB assay (Smith and Levander 
2002).  In A549 cells TrxR was inhibited at 6 µM MMAIII (Table 3).  It should be noted 
that even though MMAIII does not effect selenoprotein synthesis or mRNA expression of 
TrxR1 in this cell type, it does inhibit the enzyme.   
 Slightly different results were obtained in WI-38 cells exposed to MMAIII.  At 
treatment with 0.2 µM MMAIII the activity of TrxR increases above that of control (Table 
3).  When cultured with 2 µM MMAIII, TrxR activity decreases compared to control, but 
some residual activity remains.  When A549 cells were exposed to 2 µM MMAIII there 
was a slight decrease in activity, but probably not enough of a decrease to be considered 
significant due to the error.  If WI-38 cells were treated with 6 µM MMAIII, the 
concentration that inhibited the enzyme in A549 cells, it would be too toxic to the cells to 
be able to properly analyze the data.  At that concentration of MMAIII, rounding and cell 
death was observed with WI-38 cells (data not shown). 
 Given that MMAIII inhibits TrxR in A549, but not necessarily WI-38 cells, it 
becomes necessary to examine the regulation of TrxR1 to try to pinpoint the mechanism 
by which MMAIII is increasing synthesis of TrxR1 mRNA in WI-38 cells.  
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Table 3.  MMAIII  significantly affects TrxR activity in both A549 and WI-38 cells 
A549 cells were cultured with 0, 2, or 6 µM MMAIII, and WI-38 cells with 0, 0.2, or 2 
µM MMAIII for 48 hours to allow for complete inhibition of TrxR before harvesting.  
Activity assays based on the reduction of DTNB were performed to determine the 
activity of TrxR.  Cell culture treatment groups were grown in duplicate and analyzed in 
duplicate.  These are representative experiments of independent triplicate experiments for 




MMAIII treatment results in activation of transcription of the TrxR1 promoter 
 The TrxR promoter is regulated by the ARE (Rundlof, Carlsten et al. 2001).  To 
test if MMAIII induces TrxR through the ARE, promoter fusion luciferase constructs were 
transfected into both cell lines.  This included a wild type TrxR1 promoter containing the 
ARE, and another construct with a mutated (Mut) ARE in the TrxR1 promoter region.  If 
MMAIII exerts any effects on the ARE of TrxR1, the same effects should not be seen in 
the mutated construct.   
 A549 cells, with the exception of MMAIII inhibiting TrxR, have shown no 
changes in selenoprotein synthesis, and mRNA expression levels of TrxR1 in response to 
MMAIII exposure.  With the transfection of the TrxR1 promoter fusion constructs there 
was no change in luciferase activity as compared to control when exposed to either 2 or 6 
µM MMAIII (Figure 17 A).  As expected the mutated ARE promoter construct’s 
luciferase activity also did not change. 
 Unlike the A549 cells, the transfected WI-38 cells with the wild-type TrxR1 ARE 
promoter fusion construct displayed increased luciferase activity with exposure to 2 µM 
MMAIII (*, p< 0.05) (Figure 17 B).  There was a slight increase with treatment with 0.2 
µM MMAIII, but not enough to be considered significant.  If MMAIII is truly stimulating 
TrxR1 production through the ARE element and thus the Nrf2-Keap1 response, then the 
mutated ARE construct should yield no change in luciferase activity with MMAIII 
exposure.  Transfected WI-38 cells with the mutant construct did indeed behave this way.  
At exposure to 0.2 and 2 µM MMAIII there was no significant change in luciferase 
activity.  This indicates that MMAIII is causing an Nrf2 response through the ARE in 
TrxR1.  TrxR1 is not the only protein that contains an ARE element in its promoter.  The 
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next logical step was to confirm that exposure to MMAIII stimulates expression of 
another protein whose synthesis is regulated at the transcriptional level by the 








Figure 17.  Treatment with MMAIII in WI-38 cells induces TrxR expression through 
the ARE 
Both cell types were transfected with TrxR1 or mutant TrxR1 (Mut) promoter fusion 
constructs.  A549 cells (A) were treated with 0, 2, or 6 µM MMAIII, and WI-38 cells (B) 
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with 0, 0.2, or 2 µM MMAIII in triplicate for 24 hours before assaying for luciferase 
activity.  Plotted luciferase activity (fold) is based on the ratio of luciferase activity to that 
of renilla, with error as standard deviation.  Student’s t-tests were performed to determine 
significance.  These are representative experiments of multiple independent experiments 
conducted in triplicate for each treatment group.  
 69
Induction of quinone reductase in WI-38 cells by MMAIII 
 The gene encoding for quinone reductase contains an ARE element in the 
promoter region, and is not known to be involved in selenium metabolism (Hintze, Wald 
et al. 2003).  A549 and WI-38 cells were transfected with a rat quinone reductase (QR) 
promoter fusion construct that contained the ARE.  If MMAIII is regulating TrxR1 
through the ARE, then the results should be the same as the transfections with wild-type 
TrxR1 in both cell types with exposure to MMAIII. 
 In A549 cells carrying the QR promoter fusion construct and exposed to MMAIII 
for 24 hours there was no change in luciferase activity between treatment groups (Figure 
18 A).  These results are similar to those obtained for the wild-type TrxR1.  However, in 
WI-38 cells transfected with the QR construct and exposed to varying concentrations of 
MMAIII, there was an increase in QR promoter fusion activity with treatment of 2 µM 
MMAIII (Figure 18 B).  This was the same concentration that stimulated luciferase 
activity in TrxR1 in this cell line.  There also was a slight increase in activity with 
treatment at 0.2 µM MMAIII, but not enough to be considered significant.   
 We have thus shown that both TrxR1 and QR are regulated at the transcriptional 
level by the Nrf2/Keap1 system with exposure to MMAIII.  This implicates the 
mechanism of MMAIII inducing TrxR1 synthesis is through the Nrf2/Keap1 response.  To 









Figure 18.  Regulation of QR in WI-38 cells by MMAIII 
A549 (A) and WI-38 (B) cells were transfected with rat quinone reductase (QR) promoter 
fusion constructs and exposed to increasing concentrations of MMAIII for 24 hours before 
assaying for luciferase and renilla activities.  The relative luciferase activity (fold) is the 
ratio of luciferase to renilla activity, with standard deviation as error.  Statistical 
 71
significance was determined by Student’s t-tests.  These are representative experiments of 
multiple independent experiments for each cell type and were conducted in triplicate.  
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CHAPTER SIX: CONCLUSIONS OF MONOMEHTYLARSONOUS ACID (III) 
STIMULATES CYTOSOLIC THIOREDOXIN REDUCTASE IN A NRF2-
DEPENDENT MANNER  
 
MMAIII is a metabolite of arsenic produced during the methylation reactions 
carried out to facilitate excretion.  It is not found in the natural environment, but is 
generated during the excretory pathway of inorganic arsenic.  It has been found to be the 
most cytotoxic of all arsenicals and could prove to be the most carcinogenic (Petrick, 
Ayala-Fierro et al. 2000; Bredfeldt, Jagadish et al. 2006).  
It has also been shown that selenium and arsenic interact according to a mutual 
sparring effect (Moxon 1938).  This means that as the levels of arsenic increase the 
amount of available selenium decreases and visa versa.  If someone is exposed to 
inorganic arsenic this will result in lower selenium levels in tissues, and could reduce 
selenium to the point that it affects selenoprotein synthesis.  When selenium levels begin 
to be depleted, there is a certain point that the cell will begin to preferentially make some 
selenoproteins over others (Low, Grundner-Culemann et al. 2000).  This is known as the 
selenoprotein hierarchy. TrxR, because of its importance in maintaining the cellular 
redox environment is one of the selenoproteins at the top of the hierarchy and will be 
expressed under selenium limiting conditions.   
 When WI-38 cells were exposed to MMAIII TrxR synthesis increased, while 
smaller selenoproteins, based on initial analysis to be cGPx, decreased as determined by 
radiolabeling with 75Se.  This phenotype with MMAIII exposure was also observed in a 
previous study with HaCat cells (human keratinocytes) (Ganyc, Talbot et al. 2007), but 
the mechanism was not yet elucidated.  It should be considered that people who do have 
MMAIII in their system as a result of exposure to arsenic, would likely have low selenium 
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levels.    Depending on the amount of exposure to arsenic they could be selenium 
compromised to a level that is lower than that used in our cell culture studies.   
Treatment with MMAIII also led to an increase in TrxR1 mRNA levels in WI-38 
cells.  This correlates with the radiolabeling data.  The decrease in cGPx mRNA levels in 
WI-38 cells also correlates with radiolabeling.  Under selenium limiting conditions, cGPx 
will not be preferentially expressed over TrxR1.   
Treatment of A549 cells with MMAIII had no effect on selenoprotein synthesis, 
expression levels or regulation.  It did however inhibit TrxR activity.  The question 
becomes what is different about the WI-38 cells from A549.  WI-38 cells are a primary 
lung fibroblast, while A549 cells were originally isolated from an adenocarcinoma and 
are therefore transformed.  One obvious difference lies in the regulation of TrxR1 and 
other ARE containing genes.  A recent study showed that A549 cells have the 
transcription factor Nrf2 constitutively localized in the nucleus (Kweon, Adhami et al. 
2006).  This suggests that all ARE containing genes are constitutively expressed and are 
no longer regulated through the Nrf2/Keap1 system.  This explains why addition of 
MMAIII did not induce upregulation of either TrxR1 and QR promoter.  The WI-38 cells 
are not derived from a tumor, and have a wild-type Nrf2/Keap1 system.  This was the key 
difference between the two cell lines in how MMAIII effects regulation of TrxR1.   
It is a novel finding that MMAIII induces TrxR1 through the ARE.  This is also 
interesting from a carcinogenic standpoint.  Many tumors have TrxR upregulated 
(Berggren, Gallegos et al. 1996; Gladyshev, Factor et al. 1998).  TrxR has also been 
suggested to be potential target for cancer therapy.  Since we have demonstrated that 
MMAIII induces TrxR1 through the Nrf2/Keap1 response, this may be part of the 
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mechanism of how exposure to MMAIII can result in carcinogenesis.  By inducing TrxR1 
the cell is not only trying to defend itself from the ROS that MMAIII can generate, but 
with more TrxR1 more thioredoxin can be reduced.  This in turn can lead to increased 
cell proliferation, DNA synthesis and resistance to apoptosis.  This combination, along 
with low selenium status and higher levels of ROS, could indeed be a recipe for 
carcinogenesis.    
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